Journal of Urgent Care Medicine

New Glucose Monitor Measures Glycemic Trends For Kids

The Food and Drug Administration (FDA) has approved the first over-the-counter continuous glucose monitor (CGM) indicated for children aged 2 years and older who do not use insulin, according to an agency news release. The wearable device continuously measures glucose levels and displays readings and trends through a smartphone application, which can be used on a caregiver’s device. Real-time glucose data—measured every 15 minutes—is intended to help children and their parents better understand the effects …

Inhaled Insulin Powder Approved For Use in Kids

The U.S. Food and Drug Administration (FDA) has expanded approval for insulin inhalation powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes, according to the product manufacturer’s press release. Previously, the inhaled insulin was only approved for adults. The oral inhaler device and insulin inhalation powder deliver insulin into the bloodstream through the lungs, enabling rapid absorption of insulin into systemic circulation. Marketed as Afrezza, …

Oral Drug Targets Chronic Hives

The Food and Drug Administration (FDA) has approved oral remibrutinib, a new drug product, as a second-line treatment for chronic spontaneous urticaria (CSU). Remibrutinib has a unique mechanism to block the activity of Bruton’s tyrosine kinase (BTK), stopping a key pathway of the immune response in CSU, according to a manufacturer press release. The condition is thought to be caused by immune dysregulation, and it is believed that once activated, BTK leads to the release …

New Oral Drug Approved For UTIs

The Food and Drug Administration (FDA) has approved the combination sulopenem etzadroxil and probenecid, an oral antibiotic, to treat bacterial urinary tract infections (UTI) in adult women caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. Manufacturer Iterum Therapeutics anticipates a commercial launch for the drug, branded as Orlynvah, in 2025, according to Reuters. The oral drug is taken twice daily for 5 days and can be used to treat uncomplicated UTIs in women who …

Login to JUCM